Is renal hamartoma surgery dangerous?

Renal hamartoma, also known as renal angiomyolipoma, is a benign tumor composed of dysplastic vascular tissue and smooth muscle. The boundary between hamartoma and normal renal tissue is unclear. In general, there may be low back pain and tumor compression symptoms such as splitting, severe pain, hematuria, nausea, vomiting, etc., which require surgical treatment. However, any surgery is dangerous, so patients must pay more attention.

Renal hamartoma is formed by blood vessels, smooth muscles, and fat. Clinically, it is an independent disease. Because the disease has a genetic tendency, it is characterized by a series of features such as brain dysplasia, epilepsy, and oral sebaceous gland adenoma. The disease is complicated and it is necessary to improve it through surgery, but the risk of surgery is very high. Patients must pay more attention. Let's learn about it below.

Renal hamartoma is a common benign renal tumor, and whether surgical treatment is harmful to the human body and whether it will affect health is highly valued. In general, the tumor is very small, with no obvious growth, no complications of cleavage and bleeding, and no surgery is required, but regular check-ups are required and no treatment is required. The tumor at this stage is harmless and will not affect kidney function and health, but if the tumor is large, continues to grow by more than 1-2cm each year, or even spontaneously cleaves and bleeds, it means that the disease is serious and requires surgical treatment, but surgery is risky and it is necessary to go to a regular hospital for it.

Generally speaking, renal hamartoma, also known as renal angiomyolipoma, is a benign tumor that can occur in the cortex and medulla. Pathological examination shows that the tumor varies in size and can grow outside the kidney. The capsule is incomplete, but the boundaries are clear. At this time, surgical treatment should be performed under a microscope according to the different conditions of fat tissue, blood vessels and smooth muscle. If the hamartoma has malignant transformation, surgical treatment is risky. After surgery, it is recommended to use ginsenoside Rh2 to activate immune cells, inhibit the growth and proliferation of cancer cells, and induce cancer cell apoptosis, thereby ensuring better treatment effects.

Renal hamartoma is difficult to treat with major surgery. In the long run, if the patient has stones or tumors in the contralateral kidney, surgical treatment is required to avoid affecting the patient's renal function and quality of life. Once a renal hamartoma is found, the appropriate surgical treatment plan should be determined based on the tumor size and clinical manifestations to reduce the risk of surgery.

Surgery for renal hamartoma has certain risks. Generally, if the renal hamartoma is small, conservative treatment is recommended. If it is large, surgery should be performed, and the recovery effect after surgery is good. It is also necessary to strengthen nutrition, exercise properly, enhance immunity, and reduce surgical risks. Different surgeries have different risks. Only when patients understand clearly can they know how to treat and thus reduce surgical risks.